Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Effect of Different Plasma Insulin Levels on the Accuracy of Continuous Subcutaneous Glucose Monitoring

24. oktober 2012 oppdatert av: Fundación para la Investigación del Hospital Clínico de Valencia

New Strategies for Automated Glycaemic Control: the Issue of Continuous Glucose Monitoring Accuracy Under Hypoglycaemic Conditions

Achieving near-normoglycaemia has been established as the main objective for most patients with diabetes. However, it is well known that intensification of treatment is associated with an increase in the frequency of hypoglycemia, especially in the context of insulin therapy. The burden of hypoglycemia in terms of psychological implications, morbidity and even mortality, explains why it has been defined as the main limiting factor to achievement of good metabolic control.

Continuous subcutaneous glucose monitoring (CGM) devices have been claimed to be useful in hypoglycemia detection/prevention, allowing theoretically for safer intensification of therapy in diabetic patients. However, accuracy of CGM devices, especially in the hypoglycemic range, raises some concerns. In fact, commercially available CGM devices estimate plasma glucose from measurements in the interstitial fluid and not in plasma. However, the relationship between plasma and interstitial glucose is not fully understood, especially under dynamic conditions, and this may explain the poor CGM performance during rapid changes in blood glucose and hypoglycemia.

In this project, the relationship between plasma and interstitial glucose will be evaluated under conditions of normal glucose concentrations and hypoglycemia. Experiments will be performed to assess the role, if any, of different plasma insulin concentrations on the accuracy of CGM.

All the information obtained may be relevant to the improvement of the ability of CGM devices to detect hypoglycemia and hypoglycemic risk.

Studieoversikt

Status

Fullført

Forhold

Intervensjon / Behandling

Studietype

Intervensjonell

Registrering (Faktiske)

14

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

  • Spania
      • Valencia, Spania, 46010
        • Servicio de Endocrinología y Nutrición, Hospital Clínico Universitario de Valencia

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 60 år (Voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Subjects with type 1 diabetes mellitus meeting all of the following criteria will be considered for admission to the study:

    • Aged between 18 and 60 years
    • Under CSII or MDI treatment for at least six months before Visit 1
    • Body mass index of between 18 and 30 kg/m2
    • HbA1c 6.0-8.5% at Visit 1
    • Normal laboratory values, ECG, and vital signs unless the investigator considered an abnormality to be clinically irrelevant
    • Women postmenopausal or using contraception judged by the investigator to be adequate (e.g., oral contraceptives, intra-uterine device or surgical treatment)

Exclusion Criteria:

  • Subjects meeting any of the following criteria will not be included in the study:

    • Pregnancy and lactation
    • History of hypersensitivity to the study medications or to drugs with similar chemical structures
    • Confirmed hypoglycaemia unawareness
    • Progressive fatal diseases
    • History of drug or alcohol abuse
    • History of positive HIV or hepatitis B or C test
    • Impaired hepatic function, as shown by, but not limited to, SGPT or SGOT of more than twice the upper limit of the normal range at visit 1
    • Impaired renal function, as shown by, but not limited to, serum creatinine > 1.5 mg/dL at visit 1
    • Clinically relevant microvascular, cardiovascular, hepatic, neurologic, endocrine or other major systemic diseases other than T1DM which could hinder implementation of the clinical study protocol or interpretation of the study results
    • Pre-planned surgery during the study
    • Blood donation of more than 500 ml during the past three months for men, or during the past six months for women
    • Mental condition rendering the subject unable to understand the nature, scope and possible consequences of the study
    • Subject unlikely to comply with clinical study protocol, e.g., uncooperative attitude, inability to return for follow-up visits, or poor likelihood of completing the study
    • Receipt of an experimental drug or use of an experimental device during the past 30 days.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Grunnvitenskap
  • Tildeling: Randomisert
  • Intervensjonsmodell: Crossover-oppdrag
  • Masking: Dobbelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Annen: High plasma insulin-Low plasma insulin
Seven out of the 14 subjects recruited in the study have been randomized to receive on the first study day a High insulin glucose clamp and on the second day a Low insulin glucose clamp (sequence 'AB')
Annen: High insulin eu-hypoglycemic clamp
Primed intravenous insulin infusion at a rate of 1mU/kg/min is given during the whole study duration. Glucose is infused at a variable rate to maintain plasma glucose concentrations 'clamped' at pre-specified levels. Plasma glucose levels will be the same in both study arms.
Annen: Low insulin eu-hypoglycemic clamp
Primed intravenous insulin infusion at a rate of 0.3mU/kg/min is given during the whole study duration. Glucose is infused at a variable rate to maintain plasma glucose concentrations 'clamped' at pre-specified levels. Plasma glucose levels will be the same in both study arms.
Annen: Low plasma insulin-High plasma insulin
Seven out of the 14 subjects recruited in the study have been randomized to receive on the first study day a Low insulin glucose clamp and on the second day a High insulin glucose clamp (sequence 'BA')
Annen: High insulin eu-hypoglycemic clamp
Primed intravenous insulin infusion at a rate of 1mU/kg/min is given during the whole study duration. Glucose is infused at a variable rate to maintain plasma glucose concentrations 'clamped' at pre-specified levels. Plasma glucose levels will be the same in both study arms.
Annen: Low insulin eu-hypoglycemic clamp
Primed intravenous insulin infusion at a rate of 0.3mU/kg/min is given during the whole study duration. Glucose is infused at a variable rate to maintain plasma glucose concentrations 'clamped' at pre-specified levels. Plasma glucose levels will be the same in both study arms.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Normalized current signal from the CGM devices
Tidsramme: 330 minutes

CGM devices are electrochemical sensors. Currently available sensors are placed in the subcutaneous tissue where they react with the glucose of the interstitial fluid giving a current signal (in nano Amperes), which is proportional to glucose concentrations. The current signal is then filtered and transformed into plasma glucose estimations through a calibration algorithm built into the CGM device.

In this study we will analyze the current signal from CGM obtained under two different experimental conditions:

  1. Eu-hypoglycemic clamp with High plasma insulin concentrations
  2. Eu-hypoglycemic clamp with relatively Low plasma insulin concentrations

This will allow for establishing the role, if any, of different plasma insulin concentrations on the accuracy of CGM to identify plasma glucose falls resulting in hypoglycaemia.

Since CGM sensors can exhibit different sensitivities to glucose concentrations, the current signal will be normalized before statistical analysis
330 minutes

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Fundación para la Investigación del Hospital Clínico de Valencia

Samarbeidspartnere

Universitat Politècnica de València

Etterforskere

  • Hovedetterforsker: Francisco Javier Ampudia-Blasco, MD, PhD, Hospital Clínico Universitario de Valencia - Fundación INCLIVA

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Generelle publikasjoner

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart

1. oktober 2011

Primær fullføring (Faktiske)

1. september 2012

Studiet fullført (Faktiske)

1. oktober 2012

Datoer for studieregistrering

Først innsendt

24. oktober 2012

Først innsendt som oppfylte QC-kriteriene

24. oktober 2012

Først lagt ut (Anslag)

26. oktober 2012

Oppdateringer av studieposter

Sist oppdatering lagt ut (Anslag)

26. oktober 2012

Siste oppdatering sendt inn som oppfylte QC-kriteriene

24. oktober 2012

Sist bekreftet

1. oktober 2012

Mer informasjon

Begreper knyttet til denne studien

Nøkkelord

Ytterligere relevante MeSH-vilkår

Andre studie-ID-numre

  • FP7-PEOPLE-2009-IEF #252085-2
  • Spanish Ministry of Science (Annet stipend/finansieringsnummer: spanish Ministry of Science, DPI2010-20764-C02-01)

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere